Cost-effectiveness of PCSK9 Inhibitors Proof in the Modeling

Robert O. Bonow; Robert A. Harrington; Clyde W. Yancy

doi:10.1001/jamacardio.2017.3656

Cost-effectiveness of PCSK9 Inhibitors Proof in the Modeling

Robert O. Bonow^*, Robert A. Harrington, Clyde W. Yancy

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Editorial › peer-review

9 Scopus citations

Original language	English (US)
Pages (from-to)	1298-1299
Number of pages	2
Journal	JAMA cardiology
Volume	2
Issue number	12
DOIs	https://doi.org/10.1001/jamacardio.2017.3656
State	Published - Dec 2017

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1001/jamacardio.2017.3656

Cite this

@article{25ad5c9c3c4d4c4aa6c30f7c07e6f0f5,

title = "Cost-effectiveness of PCSK9 Inhibitors Proof in the Modeling",

author = "Bonow, {Robert O.} and Harrington, {Robert A.} and Yancy, {Clyde W.}",

note = "Funding Information: completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Harrington reported receiving fees from Amgen, Bayer, Gilead, Merck, MyoKardia, the Medicines Company, and WebMD; receiving grant funding from Astra Zeneca, Bristol-Myers Squibb, CSL Limited, Glaxo SmithKline, Janssen, Merck, Novartis, Portola, Sanofi Aventis, and the Medicines Company; holding equity in Element Science and Scanadu; and holding an unpaid seat on the board of directors of the American Heart Association. No other disclosures are reported.",

year = "2017",

month = dec,

doi = "10.1001/jamacardio.2017.3656",

language = "English (US)",

volume = "2",

pages = "1298--1299",

journal = "JAMA Cardiology",

issn = "2380-6583",

publisher = "American Medical Association",

number = "12",

}

TY - JOUR

T1 - Cost-effectiveness of PCSK9 Inhibitors Proof in the Modeling

AU - Bonow, Robert O.

AU - Harrington, Robert A.

AU - Yancy, Clyde W.

N1 - Funding Information: completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Harrington reported receiving fees from Amgen, Bayer, Gilead, Merck, MyoKardia, the Medicines Company, and WebMD; receiving grant funding from Astra Zeneca, Bristol-Myers Squibb, CSL Limited, Glaxo SmithKline, Janssen, Merck, Novartis, Portola, Sanofi Aventis, and the Medicines Company; holding equity in Element Science and Scanadu; and holding an unpaid seat on the board of directors of the American Heart Association. No other disclosures are reported.

PY - 2017/12

Y1 - 2017/12

UR - http://www.scopus.com/inward/record.url?scp=85040001292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040001292&partnerID=8YFLogxK

U2 - 10.1001/jamacardio.2017.3656

DO - 10.1001/jamacardio.2017.3656

M3 - Editorial

C2 - 29049827

AN - SCOPUS:85040001292

VL - 2

SP - 1298

EP - 1299

JO - JAMA Cardiology

JF - JAMA Cardiology

SN - 2380-6583

IS - 12

ER -

Cost-effectiveness of PCSK9 Inhibitors Proof in the Modeling

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this